Mycelial biotransformation of selenium-enriched polysaccharides from Pleurotus nebrodensis suppress breast cancer via mitochondrial apoptosis and immune microenvironment remodeling.

Authors

Si-Meng Liu, Jia-Li Hu, Meng Yuan, Yan Ding, Chang-Cheng Zhao, Ling-Bo Qu, Yan-Zeng Li, Ran Yang, Hua-Jin Zeng

Published in

International journal of biological macromolecules. Pages 154358. Sep 06, 2026. Epub Sep 06, 2026.

Abstract

Selenium-enriched polysaccharides (Se-Ps) have attracted growing interest as promising antitumor agents; however, the potential of Pleurotus nebrodensis (PN) mycelium as a biotransformation carrier for Se-Ps production remains unexplored. This study aimed to develop a mycelial culture system for Se-Ps production and to elucidate their anti-breast cancer mechanisms. Selenium-enriched PN mycelia were obtained by supplementing the medium with sodium selenite at optimized concentration of 50 mg/L. Two purified Se-Ps fractions, Se-PNP-1 and Se-PNP-2, were isolated via water extraction-alcohol precipitation followed by DEAE-52 chromatography. Structural analyses confirmed selenium incorporation and revealed that Se-PNP-2, with a higher selenium content, exhibited a lower molecular weight and random coil conformation, which correlated with its superior bioactivity. In vitro, Se-PNP-2 dose-dependently suppressed 4 T1 cell proliferation (IC₅₀ = 292.4 μg/mL), migration, and invasion, and induced early apoptosis. In vivo, oral administration of Se-PNP significantly inhibited orthotopic 4 T1 tumor growth without observable toxicity, comparable to cyclophosphamide. Mechanistically, Se-PNP indirectly remodeled the tumor immune microenvironment by increasing TNF-α and IFN-γ while suppressing IL-10 and TGF-β1, and upregulated the Bax/Bcl-2 ratio and cleaved Casp3/Parp levels, indicating activation of the mitochondrial apoptosis pathway. These findings establish mycelial biotransformation as a feasible strategy for producing bioactive Se-Ps and position Se-PNP as a promising candidate for breast cancer therapy, with dual direct cytotoxic and immunomodulatory actions.

PMID:
42702312
Bibliographic data and abstract were imported from PubMed on 07 Sep 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.